Known side effects at standard doses include delayed gastric emptying, gallbladder-related issues, and more rarely, a risk for acute pancreatitis, though as mentioned above these appear to be less common at lower doses
But we just got the first good trial anddespite what you might have heardits not very encouraging
Jensen AB, Renstrm F, Aczl S, Folie P, Biraima-Steinemann M, Beuschlein F, et al
Nevertheless, results from large cardiovascular outcome trials relating to the use of GLP-1 agonists indicate that the proportion of participants discontinuing GLP-1 receptor agonists due to adverse gastrointestinal events ranges between 4.5 to 13% (100)
So youll be improving the quality of your GLP-1 treatment